Compare TSLX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | RCKT |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 277.7M |
| IPO Year | 2011 | 2014 |
| Metric | TSLX | RCKT |
|---|---|---|
| Price | $17.19 | $2.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $19.52 | $8.82 |
| AVG Volume (30 Days) | 471.5K | ★ 1.6M |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | ★ 10.15% | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | ★ 0.51 | 0.23 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.15 | $1,494.26 |
| P/E Ratio | $34.22 | ★ $9.43 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.04 | $2.15 |
| 52 Week High | $22.84 | $5.45 |
| Indicator | TSLX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 35.46 |
| Support Level | $16.66 | N/A |
| Resistance Level | $17.94 | $2.73 |
| Average True Range (ATR) | 0.43 | 0.18 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 1.21 | 12.50 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.